Jonathan S. Duke-Cohan

Dr. Jonathan S. Duke-Cohan

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AMAlexander J. McAdam
Alexander J. McAdam
TCTammy T. Chang
Tammy T. Chang
ALAnna E Lumelsky
Anna E Lumelsky
EGEdward A Greenfield
Edward A Greenfield
VBVassiliki A Boussiotis
Vassiliki A Boussiotis
GFGordon J. Freeman
Gordon J. Freeman
The inducible costimulatory (ICOS) molecule is expressed by activated T cells and has homology to CD28 and CD152. ICOS binds B7h, a molecule expressed by APC with homology to CD80 and CD86. To investigate regulation of ICOS expression and its role in Th responses we developed anti-mouse ICOS mAbs and ICOS-Ig fusion protein. Little ICOS is expressed by freshly isolated mouse T cells, but ICOS is rapidly up-regulated on most CD4+ and CD8+ T cells following stimulation of the TCR. Strikingly, ICOS up-regulation is significantly reduced in the absence of CD80 and CD86 and can be restored by CD28 stimulation, suggesting that CD28-CD80/CD86 interactions may optimize ICOS expression. Interestingly, TCR-transgenic T cells differentiated into Th2 expressed significantly more ICOS than cells differentiated into Th1. We used two methods to investigate the role of ICOS in activation of CD4+ T cells. First, CD4+ cells were stimulated with beads coated with anti-CD3 and either B7h-Ig fusion protein or control Ig fusion protein. ICOS stimulation enhanced proliferation of CD4+ cells and production of IFN-γ, IL-4, and IL-10, but not IL-2. Second, TCR-transgenic CD4+ T cells were stimulated with peptide and APC in the presence of ICOS-Ig or control Ig. When the ICOS:B7h interaction was blocked by ICOS-Ig, CD4+ T cells produced more IFN-γ and less IL-4 and IL-10 than CD4+ cells differentiated with control Ig. These results demonstrate that ICOS stimulation is important in T cell activation and that ICOS may have a particularly important role in development of Th2 cells.

21 April 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YXYanping Xiao
Yanping Xiao
SYSanhong Yu
Sanhong Yu
BZBaogong Zhu
Baogong Zhu
DBDenis Bedoret
Denis Bedoret
XBXia Bu
Xia Bu
GFGordon J. Freeman
Gordon J. Freeman
We report that programmed death ligand 2 (PD-L2), a known ligand of PD-1, also binds to repulsive guidance molecule b (RGMb), which was originally identified in the nervous system as a co-receptor for bone morphogenetic proteins (BMPs). PD-L2 and BMP-2/4 bind to distinct sites on RGMb. Normal resting lung interstitial macrophages and alveolar epithelial cells express high levels of RGMb mRNA, whereas lung dendritic cells express PD-L2. Blockade of the RGMb–PD-L2 interaction markedly impaired the development of respiratory tolerance by interfering with the initial T cell expansion required for respiratory tolerance. Experiments with PD-L2–deficient mice showed that PD-L2 expression on non–T cells was critical for respiratory tolerance, but expression on T cells was not required. Because PD-L2 binds to both PD-1, which inhibits antitumor immunity, and to RGMb, which regulates respiratory immunity, targeting the PD-L2 pathway has therapeutic potential for asthma, cancer, and other immune-mediated disorders. Understanding this pathway may provide insights into how to optimally modulate the PD-1 pathway in cancer immunotherapy while minimizing adverse events.

11 March 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NMNavin R. Mahadevan
Navin R. Mahadevan
Erik KnelsonErik Knelson
Erik Knelson
JWJacquelyn O. Wolff
Jacquelyn O. Wolff
AVAmir Vajdi
Amir Vajdi
MSMaria Saigí
Maria Saigí
DBDavid A Barbie
David A Barbie
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates MHC I, enriching for durable ICB benefit. In vitro modeling confirms epigenetic recovery of MHC I in SCLC following loss of neuroendocrine differentiation, which tracks with derepression of STING. Transient EZH2 inhibition expands these nonneuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. Consistent with these findings, murine nonneuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. Therapeutically, EZH2 inhibition followed by STING agonism enhances T-cell recognition and rejection of SCLC in mice. Together, these data identify MHC I as a novel biomarker of SCLC immune responsiveness and suggest novel immunotherapeutic approaches to co-opt SCLC's intrinsic immunogenicity. Significance: SCLC is poorly immunogenic, displaying modest ICB responsiveness with rare durable activity. In profiling its plasticity, we uncover intrinsically immunogenic MHC Ihi subpopulations of nonneuroendocrine SCLC associated with durable ICB benefit. We also find that combined EZH2 inhibition and STING agonism uncovers this cell state, priming cells for immune rejection. This article is highlighted in the In This Issue feature, p. 1861

17 March 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
NPNikolaos Patsoukis
Nikolaos Patsoukis
JDJonathan S. Duke-Cohan
Jonathan S. Duke-Cohan
ACApoorvi Chaudhri
Apoorvi Chaudhri
HAHalil-Ibrahim Aksoylar
Halil-Ibrahim Aksoylar
QWQi Wang
Qi Wang
VBVassiliki A. Boussiotis
Vassiliki A. Boussiotis
Programmed cell death-1 (PD-1) inhibits T cell responses. This function relies on interaction with SHP-2. PD-1 has one immunoreceptor tyrosine-based inhibitory motif (ITIM) at Y223 and one immunoreceptor tyrosine-based switch motif (ITSM) at Y248. Only ITSM-Y248 is indispensable for PD-1-mediated inhibitory function but how SHP-2 enzymatic activation is mechanistically regulated by one PD-1 phosphotyrosine remains a puzzle. We found that after PD-1 phosphorylation, SHP-2 can bridge phosphorylated ITSM-Y248 residues on two PD-1 molecules via its amino terminal (N)-SH2 and carboxyterminal (C)-SH2 domains forming a PD-1: PD-1 dimer in live cells. The biophysical ability of SHP-2 to interact with two ITSM-pY248 residues was documented by isothermal titration calorimetry. SHP-2 interaction with two ITSM-pY248 phosphopeptides induced robust enzymatic activation. Our results unravel a mechanism of PD-1: SHP-2 interaction that depends only on ITSM-Y248 and explain how a single docking site within the PD-1 cytoplasmic tail can activate SHP-2 and PD-1-mediated inhibitory function.

1 February 2019 in Science
Verified
Journal Article
Closed access
PDF file
RBRowan D. H. Barrett
Rowan D. H. Barrett
SLStefan Laurent
Stefan Laurent
RMRicardo Mallarino
Ricardo Mallarino
SPSusanne Pfeifer
Susanne Pfeifer
CXCharles C. Y. Xu
Charles C. Y. Xu
HHHopi E. Hoekstra
Hopi E. Hoekstra
How natural selection affects mouse coat color: Evolution, at its core, involves changes in the frequency of alleles subject to natural selection. But identifying the target of selection can be difficult. Barrett et al. investigated how allele frequencies affecting pigmentation change over time (see the Perspective by Pelletier). Wild-caught mice ( Peromyscus maniculatus ) were exposed to avian predators against naturally occurring dark or light backgrounds. Natural selection yielded shifts in coloration owing to genetic variants in the mouse coat color Agouti gene. Science , this issue p. 499 ; see also p. 452

1 March 1999 in Nature
Verified
Journal Article
Closed access
Teresa M. GunnTeresa M. Gunn
Teresa M. Gunn
KMKimberly A. Miller
Kimberly A. Miller
LHLin He
Lin He
RHRichard W. Hyman
Richard W. Hyman
RDRonald W. Davis
Ronald W. Davis
GBGregory S. Barsh
Gregory S. Barsh